Amoxicillin high-dose dual therapy for <i>Helicobacter pylori</i> primary eradication: Proton pump inhibitor and potassium-competitive acid blocker, which’s better?
The HDDT based on vonoprazan demonstrated non-inferiority to the VAC triple regimen, suggesting its potential as a recommended first-line treatment for <i>H. pylori</i> eradication. While B-quadruple therapy showed better eradication rate than EA therapy, the latter proved non-inferior in mITT and PP analyses. Notably, antibiotic use within the preceding two years, adherence to treatment protocols, and patient residence emerged as critical factors influencing eradication success.
Authors
- Yu Liu (ORCID: https://orcid.org/0000-0002-7968-0162)
- Lunxi Liang (ORCID: https://orcid.org/0000-0003-4178-9055)
- Fen Wang (ORCID: https://orcid.org/0000-0002-1387-1126)
- Shanshan Yao (ORCID: https://orcid.org/0000-0002-2125-1242)
- Xiaoming Liu (ORCID: https://orcid.org/0000-0002-1811-8758)
- Xiuyan Yang (ORCID: https://orcid.org/0009-0003-8186-650X)
- Suxin Zhang (ORCID: https://orcid.org/0000-0003-3896-9565)
- Shengjun Zhang
Institutions
- Central South University (CN)
- Third Xiangya Hospital (CN)
Publication Details
- Journal
- World Journal of Gastroenterology
- Published
- 2025-04-02
- DOI
- https://doi.org/10.3748/wjg.v31.i13.100863
- Citations
- 7
- Primary Topic
- Helicobacter pylori-related gastroenterology studies
- Type
- article
- Field-Weighted Citation Impact
- 14.04